Search Ontology:
ChEBI

savolitinib

Term ID
CHEBI:231369
Synonyms
  • 1-[(1S)-1-(imidazo[1,2-a]pyridin-6-yl)ethyl]-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine
  • 1-[(1S)-1-imidazo[1,2-a]pyridin-6-ylethyl]-6-(1-methyl-1H-pyrazol-4-yl)-1H-1,2,3-triazolo[4,5-b]pyrazine
  • 3-[(1S)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine
  • AZD 6094
  • AZD-6094
  • AZD6094
  • HM 5016504
  • HM-5016504
  • HMPL 504
  • HMPL-504
  • Orpathys
  • savolitinib
  • savolitinibum
  • volitinib
Definition
A member of the class of triazolopyrazines that is 1H-[1,2,3]triazolo[4,5-b]pyrazine substituted by (1S)-1-(imidazo[1,2-a]pyridin-6-yl)ethyl and 1-methyl-1H-pyrazol-4-yl groups at positions 1 and 6, respectively. It is a highly selective MET tyrosine kinase inhibitor that is approved in China for advanced NSCLC with MET exon 14 skipping mutations.
References
  • cas:1313725-88-0
  • drugbank:DB12048
  • kegg.drug:D11139
  • pdb-ccd:V0L
  • pubmed:25148209
  • pubmed:25779944
  • pubmed:28644771
  • pubmed:29191878
  • pubmed:30952639
  • pubmed:31531204
  • pubmed:31564914
  • pubmed:32027846
  • pubmed:32469384
  • pubmed:33052556
  • pubmed:33125717
  • pubmed:33400845
  • pubmed:34455538
  • pubmed:34590028
  • pubmed:36333268
  • pubmed:36339926
  • pubmed:36551608
  • pubmed:36808891
  • pubmed:36809050
  • pubmed:36811415
  • pubmed:36846984
  • pubmed:36888921
  • pubmed:36944506
  • pubmed:37078211
  • pubmed:37293311
  • pubmed:37315260
  • pubmed:37564044
  • pubmed:37835402
  • pubmed:38023194
  • pubmed:38145112
  • pubmed:38181277
  • pubmed:38182507
  • pubmed:38276867
  • pubmed:38313385
  • pubmed:38380365
  • pubmed:38385995
  • pubmed:38525101
  • pubmed:38599970
  • wikipedia.en:Savolitinib
Ontology
ChEBI  ( EBI )
Relationships
Phenotype
Phenotype resulting from savolitinib
Phenotype where environments contain savolitinib
Phenotype modified by environments containing savolitinib
Phenotype affecting savolitinib
Human Disease Model